- Home
- NSTS vs ANL Comparison
NSTS vs ANL Comparison
Compare NSTS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NSTS | ANL |
|---|---|---|
| Founded | 1921 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 350.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NSTS | ANL |
|---|---|---|
| Price | $12.25 | $8.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 1.8K | ★ 459.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $256,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $0.88 |
| 52 Week High | $13.06 | $12.09 |
Technical Indicators
Market Signals| Indicator | NSTS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 52.82 |
| Support Level | $11.91 | $1.36 |
| Resistance Level | $12.74 | $12.09 |
| Average True Range (ATR) | 0.20 | 0.82 |
| MACD | -0.00 | -0.47 |
| Stochastic Oscillator | 38.60 | 36.73 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.